NCT05016947 2026-01-29
Venetoclax Plus Inotuzumab for B-ALL
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
Dana-Farber Cancer Institute
Thomas Jefferson University
Children's Oncology Group
National Cancer Institute (NCI)
Children's Oncology Group